Comparing treatment timing in recurrent nasopharyngeal cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial compares giving chemotherapy and immunotherapy before surgery (neoadjuvant) versus after surgery (adjuvant) for patients whose nasopharyngeal cancer has returned locally. It aims to find which approach works better to control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have nasopharyngeal cancer that has come back after completing your first radiation treatment.
- The tumor is removable with surgery and is at a certain stage (T2 deep, T3 not in sphenoid sinus only, or T4).
- You are between 18 and 75 years old.
- Your general health is good enough to undergo surgery, chemotherapy, and immunotherapy (ECOG score 0-2).
- You do not have other serious medical conditions or active autoimmune diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether adding chemo-immunotherapy after surgery is better than surgery alone for patients whose nasopharyngeal cancer has returned but is still in early stages. It may help prevent the cancer from coming back again.
This trial compares two treatments for early-stage nasopharyngeal cancer that has returned after radiation: surgery versus intensity-modulated radiation therapy (IMRT). The goal is to see which approach is more effective at controlling the cancer while keeping side effects manageable.
This trial studies toripalimab (an immunotherapy that helps your immune system attack cancer) for nasopharyngeal cancer that has come back locally. It may help shrink or control the returning tumor and improve outcomes for people who meet the safety and lab requirements.
This trial tests giving chemotherapy before and after surgery for people whose nasal cancer has come back. The goal is to see if this approach helps remove the cancer more effectively and prevents it from returning again.
This phase 3 trial tests whether adding toripalimab (an immunotherapy medicine) to standard chemo-radiation works better for treating nasopharyngeal cancer that has come back and cannot be removed by surgery. It aims to improve control of the cancer after it returns.
This trial tests a combination of two chemotherapy drugs (called TC) given after surgery to remove a nasopharyngeal cancer that has come back locally. The goal is to see if this treatment helps prevent the cancer from returning again and is safe for patients.
Hear when a new Recurrent Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.